A Phase 2 interventional study of AbobotulinumtoxinA dose 1 and Placebo in Platysmal Bands, sponsored by Galderma R&D. Completed at 8 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-26.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Interventional phase 2 study to evaluate safety and efficacy of abobotulinumtoxinA for the treatment of platysmal bands.
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
AbobotulinumtoxinA dose 1 injected into platysma bands
Biological: AbobotulinumtoxinA dose 1
placebo injected into platysma bands
Other: Placebo
AbobotulinumtoxinA dose 2 injected into platysma bands
Biological: AbobotulinumtoxinA dose 2
AbobotulinumtoxinA dose 3 injected into platysma bands
Biological: AbobotulinumtoxinA dose 3
Treatment of platysmal bands
Treatment of platysmal bands
Treatment of platysmal bands
Treatment of platysmal bands
Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo
A responder is defined as a subject who achieves grade 1 or 2 in platysmal band severity on the Investigator Live Assessment (ILA).
Time frame: Month 1 after treatment
| Milestone | Placebo | AbobotulinumtoxinA Dose 1 |
|---|---|---|
| Started | 20 | 60 |
| Completed | 18 | 58 |
| Not completed | 2 | 2 |
A responder is defined as a subject who achieves grade 1 or 2 in platysmal band severity on the Investigator Live Assessment (ILA).
| Participants | Placebo | AbobotulinumtoxinA Dose 1 |
|---|---|---|
| Responder Rate at Month 1 for a Single Dose of abobotulinumtoxinA Compared to Placebo | 3 | 36 |
Collected over 5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/20 (0%) | 0/20 (0%) | 7/20 (35%) |
| AbobotulinumtoxinA Dose 1 | 0/60 (0%) | 0/60 (0%) | 14/60 (23.3%) |
| Event | Placebo | AbobotulinumtoxinA Dose 1 |
|---|---|---|
| Injection site bruisingGeneral disorders | 1/20 | 5/60 |
| DiplopiaEye disorders | 1/20 | 0/60 |
| Dry EyeEye disorders | 1/20 | 0/60 |
| DysphagiaGastrointestinal disorders | 0/20 | 3/60 |
| Dental CariesGastrointestinal disorders | 1/20 | 0/60 |
| Injection site heamorrhageGeneral disorders | 0/20 | 3/60 |
| Injection site swellingGeneral disorders | 1/20 | 0/60 |
| MalaiseGeneral disorders | 1/20 | 0/60 |
| Viral upper respiratory tract infectinonInfections and infestations | 1/20 | 2/60 |
| Musculoskeletal discomfortMusculoskeletal and connective tissue disorders | 1/20 | 1/60 |
Due to business decision study did not proceed to enroll dose 2 or dose 3.
| Age, Categorical(Participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 20 | 60 | 80 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| Mean | 50.6 ± 8.56 | 52.1 ± 7.74 | 51.7 ± 7.93 |
| Sex: Female, Male(Participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| Female | 20 | 58 | 78 |
| Male | 0 | 2 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 11 | 14 |
| Not Hispanic or Latino | 17 | 49 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 18 | 57 | 75 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| United States | 20 | 60 | 80 |
| Fitzpatrick Skin Type (FST)(Participants) | Placebo | AbobotulinumtoxinA Dose 1 | Total |
|---|---|---|---|
| FST I | 0 | 0 | 0 |
| FST II | 9 | 17 | 26 |
| FST III | 5 | 25 | 30 |
| FST IV | 4 | 15 | 19 |
| FST V | 1 | 1 | 2 |
| FST VI | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Dec 2019, 3 months.
Results were first posted in Jan 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.